Search - tctmd.com

Displaying 101 - 120 of 255

Sort: Relevancy | Date

News Daily News

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Michael O'Riordan

December 07, 2022

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Lowering BP Boosts CV Health Irrespective of Diabetes: Meta-analysis

Todd Neale

August 02, 2022

News Daily News

CV Risk Factors, Disease Projected to Explode in Coming Decades

L.A. McKeown

August 01, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

Todd Neale

July 19, 2022

News Daily News

‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health

L.A. McKeown

July 04, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Daily News

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Michael O'Riordan

June 17, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News SCAI 2022

Low Household Income Predicts Risk of Death During STEMI Hospitalization

L.A. McKeown

May 19, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

Advertisement

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

A Simple Nudge Moves the Needle on Statin Prescribing

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

What’s Going to Be Hot at ESC 2022?

Lowering BP Boosts CV Health Irrespective of Diabetes: Meta-analysis

CV Risk Factors, Disease Projected to Explode in Coming Decades

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

CVD, Diabetes Spike in Acute Phase of COVID-19

‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Dapagliflozin Boosts Health Status Across LVEF Range

Low Household Income Predicts Risk of Death During STEMI Hospitalization

Good News and Bad for High-Intensity Statin Use in ASCVD

FDA Approves Empagliflozin for Treatment of HFpEF

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content